Literature DB >> 16818773

Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.

Anna Ibáñez1, Maria-Rosa Sarrias, Montserrat Farnós, Idoia Gimferrer, Carles Serra-Pagès, Jordi Vives, Francisco Lozano.   

Abstract

CD6 is a cell surface receptor primarily expressed on immature thymocytes and mature T and B1a lymphocytes. Through its binding to activated leukocyte cell adhesion molecule (ALCAM/CD166), CD6 is considered to play an important role in lymphocyte development and activation. Accordingly, CD6 associates with the TCR/CD3 complex and colocalizes with it at the center of the mature immunological synapse on T lymphocytes. Moreover, the CD6-ALCAM interaction has been shown to be critical for proper immunological synapse maturation and T cell proliferative responses. However, the precise biological effects of CD6 ligation and its signaling pathway are still not well understood. The present study shows that CD6 ligation with three different specific mAbs (161.8, SPV-L14.2, and MAE1-C10) induces time- and dose-dependent activation of ERK1/2 on normal and leukemic human T cells. This effect was also observed upon CD6 ligation with a chimerical ALCAM protein (ALCAM-Fc). The C-terminal cytoplasmic region of CD6, as well as Src tyrosine kinases, was critical for CD6-induced ERK1/2 activation. Synergistic effects were observed upon coligation of the TCR/CD3 complex with CD6. The ligation of CD6 induced the transcriptional activation of reporter genes under the control of the c-Fos serum responsive element and AP-1. Accordingly, CD6-mediated activation of p38 and JNK was also observed. These findings indicate that the CD6-ALCAM interaction results in activation of the three MAPK cascades, likely influencing the dynamic balance that determines whether resting or activated lymphocytes survive or undergo apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818773     DOI: 10.4049/jimmunol.177.2.1152

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Alcama mediates Edn1 signaling during zebrafish cartilage morphogenesis.

Authors:  Priya Choudhry; Deepa Joshi; Birgit Funke; Nikolaus Trede
Journal:  Dev Biol       Date:  2010-11-10       Impact factor: 3.582

2.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

3.  Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Authors:  Lazaro E Aira; Patricia Hernández; Dinorah Prada; Araceli Chico; Jorge A Gómez; Zuyén González; Karla Fuentes; Carmen Viada; Zaima Mazorra
Journal:  MAbs       Date:  2015-10-15       Impact factor: 5.857

4.  The role of CD6 in autoimmune diseases.

Authors:  David A Fox
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

5.  Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis.

Authors:  Marta Consuegra-Fernández; Marc Julià; Mario Martínez-Florensa; Fernando Aranda; Cristina Català; Noelia Armiger-Borràs; María-Teresa Arias; Francisca Santiago; Antonio Guilabert; Anna Esteve; Carlos Muñoz; Carlos Ferrándiz; José-Manuel Carrascosa; Edurne Pedrosa; Jorge Romaní; Mercè Alsina; José-Manuel Mascaró-Galy; Francisco Lozano
Journal:  Cell Mol Immunol       Date:  2017-12-11       Impact factor: 11.530

6.  Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6.

Authors:  Yan Li; Jeffrey H Ruth; Stephanie M Rasmussen; Kalana S Athukorala; Daniel P Weber; M Asif Amin; Phillip L Campbell; Nora G Singer; David A Fox; Feng Lin
Journal:  Arthritis Rheumatol       Date:  2020-08-14       Impact factor: 10.995

7.  Serum free cultured bone marrow mesenchymal stem cells as a platform to characterize the effects of specific molecules.

Authors:  Leonardo Solmesky; Sharon Lefler; Jasmine Jacob-Hirsch; Shlomo Bulvik; Gideon Rechavi; Miguel Weil
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Authors:  Lazaro E Aira; Alejandro López-Requena; Dasha Fuentes; Liset Sánchez; Teresita Pérez; Aleida Urquiza; Heber Bautista; Leopoldina Falcón; Patricia Hernández; Zaima Mazorra
Journal:  MAbs       Date:  2014-03-04       Impact factor: 5.857

9.  A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors:  Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal:  Results Immunol       Date:  2012-11-21

10.  CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock.

Authors:  Maria-Rosa Sarrias; Montserrat Farnós; Rubén Mota; Fernando Sánchez-Barbero; Anna Ibáñez; Idoia Gimferrer; Jorge Vera; Rafael Fenutría; Cristina Casals; José Yélamos; Francisco Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.